Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Aug 10, 2018 8:43am
213 Views
Post# 28439387

RE:RE:RE:What could be the bad news ?

RE:RE:RE:What could be the bad news ?This is what Artisan wrote in their monthly update

"Specialty pharmaceutical company Theratechnologies—one of our top contributors in Q2—was our biggest decliner in July. The stock essentially “round-tripped” back to late-April prices as investors took profits after Q2’s sharp gains. We are not too concerned with the stock’s pullback and remain positive on the company’s fundamental outlook. The company’s new HIV medication Ibalizumab (branded as TrogarzoTM)—approved by the FDA in March and launched in April—is a key catalyst for earnings growth. "

https://www.artisanpartners.com/content/dam/documents/monthly-commentary/vr/2018/jul/ARTJX-MCommentary-0718-vR.pdf

JayjayUSA12007 wrote:
I can see Artisan sold at $USD 8 and above but not at this level, unless they are liquidating their fund which I doubt it.
The last 3 month dump seemed to be very organized, not erratic as in panic sale. Very systemic sale !


Bullboard Posts